Questions: Mast Cells and Basophils in Allergic and Innate Responses

Question 1

A patient with allergic asthma takes an antihistamine before allergen exposure. They experience minimal immediate symptoms but still develop significant bronchoconstriction and chest tightness 6–8 hours later. Which mediators are most responsible for this late-phase response?

• A. Histamine released from newly recruited basophils during the late phase, which antihistamines do not reach
• B. Leukotrienes (LTC4, LTD4, LTE4) and cytokines (IL-4, IL-5, IL-13) synthesized de novo after the initial trigger and released over hours
• C. IgE antibodies that persist in the tissue and continue cross-linking FcεRI receptors throughout the day
• D. Complement fragments (C3a, C5a) generated by the late-phase cellular infiltrate

Answer: (B)

Antihistamines block H1 receptors and effectively suppress the acute immediate phase (within minutes). The late phase (4–8 hours later) is driven not by histamine but by lipid mediators synthesized de novo after the initial trigger — especially leukotrienes LTC4, LTD4, and LTE4, which are far more potent bronchoconstrictors than histamine — and by cytokines (IL-4, IL-5, IL-13, TNF-α) that recruit eosinophils, basophils, and Th2 cells. This is why asthma management requires anti-inflammatory agents (inhaled corticosteroids, leukotriene antagonists), not just antihistamines.

Question 2

Mast cells are concentrated at body-environment interfaces — skin, airway mucosa, gastrointestinal tract, and perivascular sites. This strategic positioning primarily reflects their:

• A. Need to receive hormonal signals from the adrenal glands to regulate degranulation thresholds
• B. Role as sentinel cells that evolved to detect and respond to pathogens and parasites entering through body surfaces
• C. Requirement for constant proximity to lymph nodes where IgE is produced and secreted by plasma cells
• D. Dependence on the high oxygen concentrations available only at tissue surfaces near blood vessels

Answer: (B)

Mast cell tissue distribution reflects their evolutionary origin as first responders to invaders entering through body interfaces — particularly helmintic parasites too large for phagocytes to engulf and certain bacteria. A mast cell in the gut mucosa, airway epithelium, or skin is positioned exactly where parasites first make contact. When allergens encounter mast cells at these same surfaces, the same defensive machinery is triggered against harmless environmental antigens — the same molecular logic, a profoundly different clinical outcome.

Question 3

Allergic diseases like anaphylaxis, asthma, and hay fever represent an evolutionary misfiring of a parasite-defense system against harmless environmental antigens using the same molecular machinery that evolved to expel helmintic worms.

• T. True
• F. False

Answer: True

The IgE/mast cell/FcεRI axis evolved under selective pressure from multicellular parasites. Anti-helminth immune responses are characterized by Th2 cytokines (IL-4, IL-5, IL-13), IgE class switching, mast cell and eosinophil activation — the identical immune profile seen in allergies. IgE-mediated mast cell degranulation at mucosal surfaces increases mucus secretion, enhances peristalsis, and recruits eosinophils to expel parasites. When this system is triggered by pollen or peanut protein, the molecular machinery is identical; only the target is different. The hygiene hypothesis proposes that reduced helminth exposure in developed countries may allow this system to 'misfire' more often.

Question 4

Histamine is the primary mediator responsible for the prolonged bronchoconstriction and chronic airway inflammation seen in asthma.

• T. True
• F. False

Answer: False

Histamine is primarily responsible for the acute immediate effects — wheal and flare, initial bronchospasm within minutes. Chronic asthmatic inflammation is driven by leukotrienes (potent, sustained bronchoconstrictors far more powerful than histamine), cytokines promoting Th2 inflammation (IL-4, IL-5, IL-13), and eosinophil-mediated structural tissue damage leading to airway remodeling. Antihistamines are effective for allergic rhinitis but are generally ineffective for controlling asthma — which reflects that histamine is not the dominant pathophysiological driver of chronic asthma.

Question 5

Why does the immediate phase of the allergic response — rapid histamine release within minutes — fail to fully explain the chronic tissue damage seen in diseases like asthma and atopic dermatitis?

Model answer: The immediate phase is driven by preformed granule contents (mainly histamine) and produces rapid but short-lived effects. Chronic allergic diseases are sustained by the late phase (4–8 hours later), in which mast cells synthesize leukotrienes and cytokines that recruit eosinophils, Th2 cells, and basophils. This sustained cellular infiltration causes structural tissue damage — airway remodeling in asthma, skin barrier disruption in atopic dermatitis — that histamine release alone cannot produce.

A patient with severe asthma has persistent airway hyperresponsiveness, mucus hypersecretion, subepithelial fibrosis, and smooth muscle hypertrophy — structural changes that persist even between acute exposures and are not driven by histamine. These reflect chronic Th2 inflammation maintained by the late-phase cytokine environment (IL-4 drives IgE switching, IL-5 drives eosinophil survival, IL-13 drives mucus production). Treating only the immediate phase with antihistamines leaves the inflammatory engine running. Effective chronic asthma management requires targeting the late-phase cytokine response with corticosteroids and the leukotriene pathway with antagonists like montelukast.